Faculty of Medicine, Peoples' Friendship University of Russia (RUDN University), 117198 Moscow, Russia.
Federal Research Center "Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences", Institute of Cell Biophysics of the Russian Academy of Sciences, 142290 Pushchino, Russia.
Viruses. 2024 Mar 9;16(3):423. doi: 10.3390/v16030423.
COVID-19 is a highly contagious respiratory disease with a high number of lethal cases in humans, which causes the need to search for new therapeutic agents. Polysaccharides could be one of the prospective types of molecules with a large variety of biological activities, especially antiviral. The aim of this work was to study the specific antiviral activity of the drug "Immeran" on a model of a new coronavirus infection SARS-CoV-2 in hamsters. Based on the second experiment, intraperitoneal treatment with the drug according to a treatment regimen in doses of 500 and 1000 μg/kg (administration after an hour, then once a day every other day, a total of 3 administrations) was effective, reliably suppressing the replication of the virus in the lungs and, at a dose of 1000 μg/kg, prevented weight loss in animals. In all cases, the treatment stimulated the formation of virus-neutralizing antibodies to the SARS-CoV-2 virus, which suggests that the drug possesses adjuvant properties.
新型冠状病毒肺炎（COVID-19）是一种高传染性的呼吸道疾病，可导致人类出现大量致死病例，因此需要寻找新的治疗药物。多糖可能是具有多种生物活性（尤其是抗病毒活性）的有前景的分子类型之一。本研究旨在以新型冠状病毒 SARS-CoV-2 感染的仓鼠模型为对象，研究药物“Immeran”的抗病毒活性。基于第二项实验，采用腹腔内治疗方式，按 500 和 1000 μg/kg 的剂量（在 1 小时后给药，然后每隔一天每天给药 1 次，共给药 3 次）进行治疗是有效的，可可靠地抑制病毒在肺部的复制，并且在 1000 μg/kg 的剂量下，可防止动物体重减轻。在所有情况下，该治疗均刺激了针对 SARS-CoV-2 病毒的病毒中和抗体的形成，这表明该药物具有佐剂特性。
